TY - JOUR T1 - Hospital length of stay for severe COVID-19 patients: implications for Remdesivir’s value JF - medRxiv DO - 10.1101/2020.08.10.20171637 SP - 2020.08.10.20171637 AU - Michaela R Anderson AU - Peter B. Bach AU - Matthew R. Baldwin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171637.abstract N2 - Remdesivir has been granted emergency use authorization for treatment of severe COVID-19. Remdesivir's pricing is based on a presumed reduction of hospital length of stay (LOS) by four days. But the Adaptive COVID-19 Treatment Trial (ACTT-1) that suggested this treatment benefit excluded patients who were expected to be discharged within 72 hours. Perhaps as a result, median time to recovery was unusually long in both arms of the study (15 days vs 11 days). Remdesivir requires a 5-day inpatient stay, so patients who would otherwise be discharged in fewer than 5 days may remain hospitalized to complete treatment while patients who would be discharged between 5 and 8 days, would only have potential reductions in their hospital LOS of 0-3 days. In a retrospective analysis of 1643 adults with severe COVID-19 admitted to Columbia University Medical Center and the Allen community hospital between March 9, 2020 and April 23, 2020, median hospital LOS was 7 (3-14) days. Five-hundred and eighty-six patients (36%) had a LOS of 1-4 days, 384 (23%) had a LOS of 5-8 days, and 673 (41%) were hospitalized for greater than or equal to 9 days. Remdesivir treatment may not provide the LOS reductions that the company relied on when pricing the therapy: 36% of the cohort would need to have LOS prolonged to receive a 5-day course, and only 41% of patients in our cohort had LOS of 9 days or more, meaning they could have their LOS shortened by 4 days and still receive a full Remdesivir course. Further investigation of shorter treatment courses and programs to facilitate outpatient intravenous Remdesivir administration are needed.Competing Interest StatementDr. Baldwin served as site co-investigator for Gilead Sciences Remdesivir trials GS-US-540-5774 and GS-US-540-5773 and received no funding. Dr. Bach reports personal fees and non-financial support from American Society for Health-System Pharmacists, personal fees from WebMD, personal fees from Defined Health, personal fees from JMP Securities, personal fees from Mercer, personal fees and non-financial support from United Rheumatology, personal fees from Foundation Medicine, personal fees from Grail, personal fees from Morgan Stanley, personal fees from NYS Rheumatology Society, personal fees and non-financial support from Oppenheimer and Co, personal fees from Cello Health, personal fees, non-financial support and other from Oncology Analytics, personal fees from Anthem, personal fees from Magellan Health, personal fees and non-financial support from Kaiser Permanente Institute for Health Policy, personal fees and non-financial support from Congressional Budget Office, personal fees and non-financial support from America's Health Insurance Plans, grants from Kaiser Permanente, grants from Arnold Ventures, personal fees and non-financial support from Geisinger, personal fees from EQRx, personal fees from Meyer Cancer Center of Weill Cornell Medicine, personal fees from National Pharmaceutical Council, outside the submitted work.Funding StatementThis study was supported in part by NIH UL1 TR001873 and the Parker B Francis Foundation. None of the listed funding sources were involved in the design or conduct of this study, the collection, management, analysis or interpretation of data, the preparation, review or approval or this manuscript, or the decision to submit this manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Columbia University IRB# AAAS9982All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing would be considered under appropriate IRB oversight and approval. ER -